ABVC BioPharma (NASDAQ:ABVC) Releases Quarterly Earnings Results, Beats Estimates By $0.37 EPS

ABVC BioPharma (NASDAQ:ABVC) posted its earnings results on Wednesday. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.37, Zacks reports.

ABVC BioPharma Price Performance

NASDAQ ABVC traded down $0.02 during trading on Wednesday, hitting $0.96. The company’s stock had a trading volume of 282,216 shares, compared to its average volume of 105,262. The company has a market cap of $25.49 million, a PE ratio of -2.40 and a beta of 0.57. The business’s 50 day simple moving average is $1.32 and its 200-day simple moving average is $1.35. ABVC BioPharma has a fifty-two week low of $0.88 and a fifty-two week high of $3.40.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Hedge Funds Weigh In On ABVC BioPharma

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of ABVC BioPharma by 5.8% in the 2nd quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock valued at $246,000 after purchasing an additional 6,017 shares during the last quarter. Citadel Advisors LLC purchased a new stake in ABVC BioPharma during the 3rd quarter worth approximately $48,000. Finally, Millennium Management LLC acquired a new position in ABVC BioPharma during the 3rd quarter valued at approximately $60,000. Institutional investors and hedge funds own 11.38% of the company’s stock.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.